News related to HIV/AIDS was marked in 2012 both by emerging therapies, as well as by the changes management strategies. Therefore, we will discuss the crucial issue of when to start antiretroviral therapy, which appears to be more and more early. Furthermore, after the U.S. validation of the pre-exposure prophylaxis for individuals at high risk of HIV acquisition, prevention of HIV transmission has returned to the spotlight. Finally, we will review some promising novel molecules whose mechanisms of action, half-life or low dosage open the door to new treatment strategies.